avatrombopag Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

  • Now
Avatrombopag is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production. Avatrombopag was discovered by Yamanouchi Pharmaceutical, developed by AkaRx which late became acquired by Dova Pharmaceuticals. In 2018 avatrombopag was approved by the FDA for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.   NCATS

  • SMILES: OC(=O)C1CCN(CC1)c2ncc(cc2Cl)C(=O)Nc3nc(c4cc(Cl)cs4)c(s3)N5CCN(CC5)C6CCCCC6
  • Mol. Mass: 649.67
  • ALogP: 6.58
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$201.2460 - $299.5560
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1-(3-chloro-5-((4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)-2-pyridyl)piperidine-4-carboxylic acid | akr501 | akr 501 | akr-501 | avatrombopag | avatrombopag maleate | e5501 | e5501 compound | e5501 maleate | ym477 | ym 477 | ym-477


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue